Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
about
Structural Basis of Targeting the Exportin CRM1 in CancerNuclear export of proteins and drug resistance in cancerAntileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaFirst-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsKPT-330 has antitumour activity against non-small cell lung cancer.Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsNucleo-cytoplasmic transport as a therapeutic target of cancerExpression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsCRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.A preclinical assay for chemosensitivity in multiple myeloma.XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.p53-based cancer therapymRNA export and cancer.Biological significance of the importin-β family-dependent nucleocytoplasmic transport pathways.The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.CRM1 Inhibitors for Antiviral Therapy.XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
P2860
Q26781513-D01FB835-AC74-4B16-AD35-1FB71A0622D6Q27012444-1D1E20EB-F115-4E1F-886C-4E6C68E58F67Q27670981-97FE80FA-2514-4C8B-9ED7-36808A857D3AQ27674083-B303646E-AE62-4F5D-92E3-7B8FD48494C5Q33430367-96647A44-0A0E-4BC8-90C9-9520DCF66D00Q33918079-4BE76282-C3D3-4848-AAC4-13A2FD31B9CCQ34410193-CE6912FD-E51D-4B66-ACC2-801E9E070EEBQ34452108-49DC9213-CB8F-46DA-8A13-69435A9CD537Q35920569-5E505A3B-68A5-43BD-AF9B-15A452BE5F61Q37203487-ECA3FD8D-6A84-4485-90F6-0F81BD525F72Q37249490-43C47530-A950-4D50-8D1C-E25C16BB31C1Q37302065-6390D6A6-DBE5-479F-A6A8-EF33C1460C6CQ37445828-F94F5968-12CC-4A29-927D-8A8B2678A8CBQ37560283-1FCB03A9-B5F8-419D-81D7-85F08DB7D203Q37684621-420A97A9-DE0C-49C8-A3EE-B5ABD108936FQ37693609-FD5EE0E1-B367-465F-BE63-494766AA93E3Q37750115-8CDDA1B2-35AE-43DA-941A-F06111020E67Q37907202-6FC61568-AA9A-4A3E-A988-0BD4AFADF16FQ38207085-A3D1A688-8B97-4104-B0BA-F7D54566D432Q39029310-98E8A362-C139-4CB6-A8CE-1B2C4FDB9629Q39141673-A73E8810-EBD0-40C4-9B05-8E9C4C367AB6Q39336778-1ED42134-DA08-468F-9600-B95E384BB9FBQ39431526-09D8E685-9F59-4D45-9B6C-0FAAD86283E6Q39643726-BA3B2CE5-77C4-484F-9BEC-53ED3DBF5720Q42057495-714B746D-F7F2-484D-BC5E-C0A5CB29E08CQ51246229-8F64F555-4E16-4C55-B645-05E324032659
P2860
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@en
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@nl
type
label
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@en
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@nl
prefLabel
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@en
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@nl
P2093
P2860
P1433
P1476
Human multiple myeloma cells a ...... inhibitors by CRM1 inhibition.
@en
P2093
Daniel M Sullivan
Douglas C Marchion
Jana L Dawson
Joel G Turner
Lori A Hazlehurst
Michael F Emmons
Peter Washausen
P2860
P304
P356
10.1158/0008-5472.CAN-09-0484
P407
P577
2009-08-18T00:00:00Z